Inhibition of IDH1 mutants with BAY1436032 resulted in differentiation of leukemic cells and leukemic blast clearance that promoted survival in AML PDX mouse models.204 A phase I study on safety and preliminary clinical effect of BAY1436032 in IDH1-mutated AML patients was completed in April 2019, but no clinical results have been published yet (NCT03127735). Here, IDH1 is linked to acute myeloid leukemia.